Brought to you by:
Merit Medical announces FDA approval of the Wrapsody cell-impermeable endoprosthesis
Merit Medical Systems announced today that the Wrapsody cell-impermeable endoprosthesis has received premarket approval from the US Food and Drug Administration (FDA). With this approval, a press release notes, Merit can begin commercialisation of the device in the USA in…
Positive one-year data for new venous valve portends promising future in chronic venous insufficiency treatment
SAVVE trial principal investigators discuss results showing 98.4% VenoValve device patency, 85% clinically meaningful benefit and an 80% rate of ulcer size reduction at 12 months. Fresh from delivering positive one-year data from the Surgical Antireflux Venous Valve Endoprosthesis (SAVVE)…
Novel bioabsorbable perivascular wrap aims to reduce AVF failure
Ellen Dillavou, MD, division chief of vascular surgery at WakeMed Heart Center in Raleigh, North Carolina, primary investigator (PI) for the VenoStent trial, presented new data during the 2024 VEITHsymposium in New York City (Nov. 19–23) about the SelfWrap (VenoStent)…
When RCTs are essential for novel vascular access device regulation
As part of a 2024 VEITHsymposium (New York City; Nov. 19–23) debate, Robert E Lee, MD, a medical officer recently retired from the Food and Drug Administration (FDA), presented an argument in favor of when the use of randomized controlled…
Venous VQI celebrates decade milestone
At the recent VEITHsymposium (Nov. 19–23) in New York City, Marc Passman, MD, reflected on the achievements of the Society for Vascular Surgery (SVS) Vascular Quality Initiative (VQI) venous arm, in collaboration with the American Venous Forum (AVF), since its…
In search of the ‘holy grail’: New analysis brings aneurysm rupture prediction closer
A rupture prediction-based algorithm is set to enhance patient selection for abdominal aortic aneurysm (AAA) repair. This is according to Randy Moore, MD, a vascular surgeon at the University of Calgary in Calgary, Canada, who, at the 2024 VEITHsymposium (Nov.…
Endothermal ablation significantly outperforms surgery for varicose veins in long-term randomized trial
Ten-year data from the randomized HELP trial show that, while both endothermal ablation and conventional surgery are effective treatments for great saphenous varicose veins at 10 years, the former was associated with superior clinical and quality-of-life (QoL) outcomes. These findings…
CPVI course: Learning the latest intricate skills and techniques to treat complex PAD
Vascular Specialist attended the SVS Complex Peripheral Vascular Interventions (CPVI) Skills Course and spoke with participants about the hands-on learning experience designed for vascular surgeons and specialists at all stages of their careers. Over two days (Sept. 28–29), participants learned…
BIO-OSCAR SOC trial examines standard of care in PAD treatment
Biotronik today announced that it has concluded the BIO-OSCAR SOC study evaluating the baseline against which to measure the Oscar multifunctional catheter in treating complex peripheral arterial disease (PAD). The outcomes were presented at the Paris Vascular Insights (PVI) course 2024…
Applications open for 2025 James S.T. Yao Resident Research Award
The SVS Foundation is accepting applications for the 2025 James S.T. Yao Resident Research Award, which supports emerging medical professionals researching vascular disease biology and innovative translational therapies. The application deadline is Jan. 8, 2025. The recipient will present their…